Skip to main content
. 2015 Aug 28;94(34):e1428. doi: 10.1097/MD.0000000000001428

FIGURE 2.

FIGURE 2

Overall survival in the HP group (n = 48): 15.5 months; in the HX group (n = 44): 17.0 months, (P = 0.78). HP = trastuzumab plus cisplatin, HX = trastuzumab plus capecitabine.